Musso, M., Scalone, R., Bonanno, V., Crescimanno, A., Polizzi, V., Porretto, F., … Perrone, T. (2009). Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Supportive Care in Cancer, 17, 205–209.
To determine the efficacy of palonosetron combined with dexamethasone in prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiple-day chemotherapy and the efficacy of a second dose of palonosetron in treating breakthrough emesis
An historic control group was used. Group O received ondansetron (8 mg IV) as a single dose on day one, along with dexamethasone each day of the regimen. Breakthrough emesis was treated with metoclopramide in the control group (but only after 72 hours following the first dose).
This study was conducted at a single inpatient setting in Palermo, Italy.
All patients were in active treatment.
This was a prospective trial with historic control comparison.
The number of vomiting episodes, grade of nausea (grading scale included), and need for rescue therapy were recorded in patient diaries.
Palonosetron was effective for prophylaxis of CINV and for treatment of breakthrough emesis in the setting of multiple-day chemotherapy.
Palonosetron demonstrates effective prevention of acute CINV in the setting of multiple-day chemotherapy regimens and treatment of breakthrough emesis when repeated 72 hours after the initial dose.